Barclays
DSGN icon

Barclays’s Design Therapeutics DSGN Stock Holding History

Barclays’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Sell
11,707
-44,083
-79% -$550K ﹤0.01% 3808
2026
Q1 		$594K Sell
55,790
-31,270
-36% -$316K ﹤0.01% 3083
2025
Q4 		$817K Sell
87,060
-1,116
-1% -$8.74K ﹤0.01% 3570
2025
Q3 		$664K Sell
88,176
-21,360
-20% -$107K ﹤0.01% 3625
2025
Q2 		$369K Buy
109,536
+25,530
+30% +$95.5K ﹤0.01% 3928
2025
Q1 		$324K Sell
84,006
-19,565
-19% -$93.3K ﹤0.01% 3784
2024
Q4 		$639K Buy
103,571
+6,936
+7% +$40.1K ﹤0.01% 3671
2024
Q3 		$520K Buy
96,635
+24,602
+34% +$116K ﹤0.01% 3752
2024
Q2 		$241K Sell
72,033
-16,875
-19% -$65.8K ﹤0.01% 3476
2024
Q1 		$358K Sell
88,908
-22,046
-20% -$58.9K ﹤0.01% 3791
2023
Q4 		$294K Buy
110,954
+39,276
+55% +$90K ﹤0.01% 4224
2023
Q3 		$169K Buy
71,678
+55,858
+353% +$261K ﹤0.01% 3376
2023
Q2 		$99.7K Sell
15,820
-1,397
-8% -$8.55K ﹤0.01% 3566
2023
Q1 		$99.3K Sell
17,217
-113,782
-87% -$851K ﹤0.01% 4184
2022
Q4 		$1.34M Buy
130,999
+109,401
+507% +$1.48M ﹤0.01% 2565
2022
Q3 		$361K Sell
21,598
-183,967
-89% -$3.66M ﹤0.01% 2872
2022
Q2 		$2.88M Sell
205,565
-20,946
-9% -$283K ﹤0.01% 1626
2022
Q1 		$3.66M Buy
+226,511
New +$3.47M ﹤0.01% 1421

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's DSGN Position: Q2 2026 in Review

Barclays reduced its Design Therapeutics (DSGN) stake by 79% in Q2 2026, selling an estimated $550K and leaving 11,707 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #3808.

Barclays first reported a position in DSGN in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.66M in Q1 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Barclays held 11,707 shares of Design Therapeutics worth $169K as of Q2 2026.
  • Barclays sold 44,083 Design Therapeutics shares in Q2 2026, an estimated $550K.
  • Design Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3808 holding.
  • Barclays first reported a position in Design Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Design Therapeutics position peaked at $3.66M in Q1 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.